Asiaticoside Encyclopedia — Scientific Background

What Is Asiaticoside?

Asiaticoside (CAS 16830-15-2), also known as madecassol or asiaticoside A, is a pentacyclic triterpenoid saponin with the molecular formula C₄₈H₇₈O₁₉ and a molecular weight of 959.13 g/mol. It is the major bioactive triterpenoid glycoside of Centella asiatica (L.) Urban, a herbaceous plant in the Apiaceae family native to wetland regions of Asia. The compound is a ursane-type triterpene glycoside and is chemically characterized as urs-12-en-28-oic acid, 2,3,23-trihydroxy-, O-6-deoxy-α-L-mannopyranosyl-(1→4)-O-β-D-glucopyranosyl-(1→6)-O-β-D-glucopyranosyl ester.

Botanical Source

Asiaticoside is extracted from the leaves of Centella asiatica (L.) Urban, commonly known as Gotu Kola or Asiatic pennywort. The plant is widely distributed in wetland regions of Asia and has been used in traditional Chinese and Ayurvedic medicine for wound healing and skin health for centuries. The active constituents of Centella asiatica include the pentacyclic triterpenes asiatic acid, madecassic acid, asiaticoside, and madecassoside, with the highest triterpenoid saponin content found in the leaves. In a study of sixty C. asiatica accessions from south India and the Andaman Islands grown under identical environmental conditions, the highest detected asiaticoside content was 1.70 ± 0.02% dry weight, indicating significant genotypic variation in triterpenoid accumulation. Asiaticoside content in C. asiatica from Madagascar has been reported between 2.6 and 6.42% dry weight.

Mechanisms of Action

Collagen Synthesis Stimulation — TβRI/Smad Pathway

Asiaticoside's most extensively documented mechanism is the stimulation of collagen synthesis in human dermal fibroblasts. Research published in Biochemical Pharmacology demonstrated that asiaticoside induces type I collagen synthesis in human dermal fibroblast cells, with the mechanisms underlying its action mediated via a TβRI kinase-independent Smad activation pathway. In cultured human fibroblasts, type I secreted collagen increased by 25–30% following treatment with asiaticoside, and mRNA levels and protein production of genes responsible for extracellular matrix synthesis, including type I and type III collagen, were significantly elevated. Asiaticoside also promotes fibroblast proliferation and extracellular matrix synthesis, which are critical for wound healing and tissue remodeling.

Wound Healing and Angiogenesis — VEGF Pathway

Asiaticoside has demonstrated wound curative ability by increasing angiogenesis and collagen formation. Research published in Life Sciences demonstrated that asiaticoside at low doses (10 pg/mL to 100 ng/mL) enhanced burn wound repair through the promotion of angiogenesis during skin wound repair, which was associated with the stimulation of VEGF production. In a study evaluating the facilitation action of asiaticoside on burn wound repair, the compound enhanced angiogenesis during skin wound repair, suggesting that the enhancement of burn wound healing by asiaticoside might be due to the promotion of angiogenesis as a result of the stimulation of VEGF production. Topical use of a 0.2% asiaticoside solution resulted in an increase in collagen content and a 57% increase in tensile strength of the healed wound.

Anti-Inflammatory Activity — NF-κB Signaling Pathway

Asiaticoside exerts potent anti-inflammatory effects through inhibition of the NF-κB signaling pathway. Research published in International Immunopharmacology demonstrated that asiaticoside suppressed inflammatory responses in LPS-induced acute lung injury through inhibition of the phosphorylation of the NF-κB p65 subunit and the degradation of its inhibitor IκBα. Asiaticoside (at doses of 30 or 45 mg/kg) dose-dependently attenuated LPS-induced pulmonary inflammation by reducing inflammatory infiltration. In a mouse model of acute lung injury, asiaticoside reduced the content of IL-6 and TNF-α and increased IL-10 in bronchoalveolar lavage fluid in a dose-dependent manner. In collagen-induced arthritis mice, asiaticoside inhibited COX-2, PGE2, TNF-α, and IL-6 production, and suppressed lymphocyte proliferation and inflammatory cell infiltration.

Neuroinflammatory Modulation

Preclinical research has demonstrated that asiaticoside modulates neuroinflammatory pathways including NF-κB and MAPK while reducing pro-inflammatory cytokines such as TNF-α and IL-6. Asiaticoside A inhibited the production of nitric oxide and TNF-α in LPS-activated primary microglia and astrocyte cultures, and ameliorated beta-amyloid-induced learning and memory deficits in rats by inhibiting mitochondrial apoptosis and reducing inflammatory factors.

The Bioavailability Challenge

Despite its broad therapeutic potential, native asiaticoside presents significant bioavailability challenges. The compound has a large molecular weight of approximately 959 g/mol and is practically insoluble in water (99 mg/L at 20°C). It is both poorly liposoluble and water-soluble, making it extremely difficult to permeate biological barriers such as the intestinal epithelium and the stratum corneum of the skin. Oral administration of Centella asiatica total glucosides failed to fulfill their therapeutic potential due to the low bioavailability of asiaticoside.

These limitations have driven the development of advanced delivery systems, including liposomes, polymeric nanoparticles, and flexible nano liposome gels. Among these, liposomal encapsulation has emerged as one of the most effective strategies for enhancing asiaticoside bioavailability, with CTG-loaded liposomes demonstrating significantly higher intestinal absorption compared to unencapsulated CTG (P < 0.05).

Liposomal Asiaticoside

Liposomal encapsulation of asiaticoside provides a fundamentally different delivery mechanism from conventional forms. The phospholipid bilayer surrounds the asiaticoside molecule, forming a protective shell that enhances stability, absorption, and cellular uptake. This delivery system:

• Achieves an average particle size of 137.0 nm with a polydispersity index of 0.283 and zeta potential of −21.2 mV

• Significantly enhances intestinal absorption compared to unencapsulated asiaticoside (P < 0.05)

• Achieves 90.80% drug encapsulation efficiency in liposome gel formulations

• Demonstrates steady-state transdermal permeation rate of 16.15 μg·cm⁻²·h⁻¹ with intradermal retention of 14.99 ± 0.58 μg/cm²

• Provides sustained release with enhanced intracellular uptake in fibroblasts within 3 hours

CTG-loaded liposomes prepared by the ethanol injection method demonstrated round, structurally intact vesicles under TEM, and DSC thermograms indicated that the CTG molecules were incorporated into the aqueous phase of DPPC liposomes, becoming more stable as a result. The significantly higher cumulative absorption amount and percentage of asiaticoside in the liposomal formulation compared to unencapsulated CTG confirm the effectiveness of liposomal encapsulation in overcoming the absorption barriers that limit asiaticoside bioavailability.

Clinical Evidence

Wound Healing — Clinical Trials

Clinical trials have evaluated Centella asiatica extracts containing asiaticoside for wound healing applications. A split-face, double-blind, randomized, placebo-controlled trial evaluated a polymeric spray film containing Centella asiatica leaf extract on acute wounds, with average healing recovery times of 4.6 ± 1.1 days for the testing group and 4.87 ± 1.0 days for the control group. The study concluded that Centella asiatica extract-containing polymeric spray film solution was beneficial as an acute wound medication, shortening healing time with no adverse effects. Innovative delivery systems such as hydrogels, nanostructures, and microneedles can accelerate wound healing, reduce wound size, and improve recovery times in various wound types, including diabetic ulcers and burns.

Scar Recovery — Clinical Studies

A clinical study investigating the synergistic effects of combined nursing interventions and asiaticosides on scar recovery and psychological well-being in patients with scald injuries demonstrated that asiaticosides exhibit promising therapeutic potential in enhancing scar recovery and psychological health in elderly scald patients when combined with comprehensive nursing care.

Skin Health and Anti-Aging

Centella asiatica is increasingly used in dermatology and cosmeceuticals for wound repair, barrier support, scar modulation, and photoaging. Preclinical and human data have demonstrated that the active constituents exert complementary actions relevant to skin biology, including stimulation of collagen synthesis and dermal matrix remodeling, and modulation of pro-inflammatory signaling. A cosmetic composition comprising multi-layered liposomes containing asiaticoside as a wrinkle active ingredient demonstrated markedly improved stability and transdermal absorption, exhibiting excellent anti-wrinkle activity.

Safety and Regulatory

Asiaticoside is generally well tolerated. Centella asiatica and its triterpenoid constituents have a long history of safe use in traditional medicine and cosmetic applications. Asiaticoside is widely commercialized as a dietary supplement ingredient, pharmaceutical agent, and cosmetic active ingredient. In the European Union, Centella asiatica preparations are regulated and introduced to the market according to their medical or food intended use. The European Medicines Agency (EMA) has evaluated Centella asiatica for traditional medicinal use, and the Committee on Herbal Medicinal Products (HMPC) has released a monograph concluding that Centella asiatica preparations are safe and effective for use. In the United States, asiaticoside is available as a dietary supplement ingredient. USP has established a reference standard for Asiaticoside (Catalog No. 1043331) to support quality control and standardization. Testing protocols must adhere to international standards including USP, European Pharmacopoeia, and FAO/WHO Codex Alimentarius. Formulators should verify local regulatory requirements prior to market entry.

This product is intended for research, nutraceutical, and functional food applications. Not intended to diagnose, treat, cure, or prevent any disease.

499$/KG

99$/KG